Hormone receptor-positive (HR +) breast cancer is the most common phenotype of the disease, and patients in first-line treatment are typically treated for endocrine disorders in advanced stages consisting of aromatase inhibitors or other medicines [7, 8]. This evidence concerns the gene CYP19A1 and breast carcinoma.